MRNA vs SBUX

Head-to-Head Stock Analysis & Investment Rating

Last Updated: Oct 04, 2026

MRNA

35.2
AI Score
VS
SBUX Wins

SBUX

59.7
AI Score

Investment Advisor Scores

MRNA

35score
Recommendation
SELL

SBUX

60score
Recommendation
HOLD

AI Analyst Insights

AI insights temporarily unavailable

Detailed Metrics Comparison

Metric MRNA SBUX Winner
Revenue 534.00M 28.77B SBUX
Net Income -2.13B 1.85B SBUX
Net Margin -397.9% 6.4% SBUX
Operating Income -2.20B 2.70B SBUX
ROE -31.4% -24.1% SBUX
ROA -19.4% 6.5% SBUX
Total Assets 10.96B 28.29B SBUX
Debt/Equity 0.09 -1.73 SBUX
Current Ratio 2.29 0.76 MRNA
Free Cash Flow -1.25B 2.72B SBUX

Relative Price Performance (Last 90 Days)

MRNA 1M: +40.0% · 3M: +156.6% SBUX 1M: -8.3% · 3M: -12.1%

Current Technical Phase

MRNA

Markup
Hold / add on dips

Price above SMA50, rising 50-day trend (49.6% over 20 days), RSI 64

RSI (14): 63.6 · Price: $196.48

SBUX

Markdown
Sell / avoid

Price below a falling SMA50 (slope -3.3%), weak momentum, RSI 35

RSI (14): 35.4 · Price: $93.58

Fundamentals Snapshot

Metric MRNA SBUX
Market Cap — —
Forward P/E -41.0 30.0
Trailing P/E — 54.6
Revenue (TTM) — —
Revenue Growth 0.0% 0.0%
Gross Margin -0.7% 0.2%
Operating Margin -5.6% 0.1%
EPS -7.36 1.76
Dividend Yield — 0.03%

Frequently Asked Questions

Based on our detailed analysis, SBUX is currently the stronger investment candidate, winning 9 of the key financial metrics based on our comprehensive scoring model.

We analyze revenue and earnings growth rates in the "Growth" section above. Generally, the company with higher year-over-year revenue and EPS growth is fostering better expansion. Check the table above for the specific growth percentages.

Valuation is determined by metrics like the P/E Ratio and PEG Ratio. A lower P/E typically suggests a stock is cheaper relative to its earnings. Refer to the "Valuation" section in our comparison table to see which stock currently trades at a more attractive multiple.